Etanercept-induced systemic lupus erythematosus

被引：57

作者：

Swale, VJ ^{[1
]}

Perrett, CM

Denton, CP

Black, CM

Rustin, MHA

机构：

[1] Royal Free Hosp, Dept Dermatol, London NW3 2QG, England

[2] Royal Free Hosp, Dept Rheumatol, London NW3 2QG, England

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2003年 / 28卷 / 06期

关键词：

D O I：

10.1046/j.1365-2230.2003.01411.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Tumour necrosis factor (TNF) is a pro-inflammatory cytokine with a role in the pathogenesis of a number of conditions including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Etanercept (Enbrel(R); Immunex Corp., Seattle, WA, USA) is a recombinant soluble fusion protein of TNF-alpha type II receptor and IgG which acts by blocking the action of TNF-alpha. It is licensed for use in rheumatoid arthritis and juvenile chronic arthritis. A number of studies report the development of antinuclear and anti-double-stranded DNA antibodies in patients treated with TNF antagonists for rheumatoid arthritis. There are few reports of the development of clinical features of discoid, subacute or systemic lupus erythematosus. We present one of the first reported cases of etenercept-induced systemic lupus erythematosus and review the literature of lupus and TNF antagonists.

引用

页码：604 / 607

页数：4

共 13 条

[1] Etanercept-induced subacute cutaneous lupus erythematosus [J].

Bleumink, GS ;

ter Borg, EJ ;

Ramselaar, CG ;

Stricker, BHC .

RHEUMATOLOGY, 2001, 40 (11) :1317-1319

[2] Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [J].

Brion, PH ;

Mittal-Henkle, A ;

Kalunian, KC .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (08) :634-634

[3] New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis [J].

Cairns, AP ;

Duncan, MKJ ;

Hinder, AE ;

Taggart, AJ .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (11) :1031-1032

[4]

Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO

[5]

2-D

[6] Biologic basis for interleukin-1 in disease [J].

Dinarello, CA .

BLOOD, 1996, 87 (06) :2095-2147

[7] Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor α-blocking agent:: Comment on the article by Pisetsky and the letter from Aringer et al [J].

Fautrel, B ;

Foltz, V ;

Frances, C ;

Bourgeois, P ;

Rozenberg, S .

ARTHRITIS AND RHEUMATISM, 2002, 46 (05) :1408-1409

[8] Drug-induced systemic lupus erythematosus and TNF-α blockers [J].

Ferraccioli, GF ;

Assaloni, R ;

Perin, A .

LANCET, 2002, 360 (9333) :645-645

[9] Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial [J].

Moreland, LW ;

Schiff, MH ;

Baumgartner, SW ;

Tindall, EA ;

Fleischmann, RM ;

Bulpitt, KJ ;

Weaver, AL ;

Keystone, EC ;

Furst, DE ;

Mease, PJ ;

Ruderman, EM ;

Horwitz, DA ;

Arkfeld, DG ;

Garrison, L ;

Burge, DJ ;

Blosch, CM ;

Lange, MLM ;

McDonnell, ND ;

Weinblatt, ME .

ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :478-+

[10]

Pisetsky DS, 2000, ARTHRITIS RHEUM, V43, P2381, DOI 10.1002/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO

← 1 2 →